Human Chorionic Gonadotropin Market: Growth, Future Prospects and Competitive Analysis, 2016-2022

Global Human Chorionic Gonadotropin Market to Reach worth USD 533.7 Mn by 2022: Infertility Prevalence and Demand for Hormonal Drugs to Influence the Market Trends

According to the latest report published by Credence Research, Inc. “Human Chorionic Gonadotropin Market (Treatments: Female Infertility, Oligospermia, Cryptorchidism & Others; Technology: Natural Source Extraction & Recombinant DNA Technology): Growth, Future Prospects and Competitive Analysis, 2016-2022,” the human chorionic gonadotropin market was valued at USD346.3 Mn in 2015, and is expected to reach USD533.7Mn by 2022, expanding at a CAGR of 6% from 2016 to 2022.

Browse the full reportHuman Chorionic Gonadotropin:Market Growth, Future Prospects and Competitive Analysis, 2016-2022report at http://www.credenceresearch.com/report/human-chorionic-gonadotropin-market

Market Insights

Infertility treatment in both males and females is the major treatment area whereHCG is commonly administered. Growing incidence of infertility in women,contributed by increased maternity age, lifestyle effects and others, hormonaldysfunctions in men and growing incidence of oligospermia are the key factors thathave supported the demand for HCG drugs in the market. The demand for HCG issteady in developed markets of Europe and North America. On the other hand,growing awareness in general population and development of healthcareinfrastructure are supporting the growth in demand for HCG drugs in emergingmarkets.

For Inquiry before buying @ http://www.credenceresearch.com/inquiry-before-buying/57982

HCG supports the normal development of egg in ovary and stimulates egg release during ovulation. It is also used for infertility treatment in women and to augmentsperm count in men. Young boys with undescended testicles are also administeredHCG treatment. Hugh prevalence of both male and female infertility issues,expanding incidence of low sperm count and sperm density in men are is the keyfactor driving the HCG...